Search research articles
Contact Us
Filters
Showing results (11-20 of 32) with videos related to
Page
of 4
Sort By:
Pediatrics
|
June 3, 2004
Does an isolated history of loss of consciousness or amnesia predict brain injuries in children after blunt head trauma?
Michael J Palchak, James F Holmes, Cheryl W Vance, et al.
Cancers
|
February 24, 2024
Comprehensive Landscape of BRAF Variant Classes, Clonalities, and Co-Mutations in Metastatic Colorectal Cancer Using ctDNA Profiling
Benny Johnson, Van Morris, Xuemei Wang, et al.
The Oncologist
|
August 10, 2022
Antibiotic Exposure Does Not Impact Immune Checkpoint Blockade Response in MSI-H/dMMR Metastatic Colorectal Cancer: A Single-Center Experience
Victoria Serpas Higbie, Jane Rogers, Hyunsoo Hwang, et al.
JCO Precision Oncology
|
October 12, 2023
Novel Clinical Tool to Estimate Risk of False-Negative KRAS Mutations in Circulating Tumor DNA Testing
Stefania Napolitano, Aparna R Parikh, Jason Henry, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 9, 2022
Resistance Mechanisms to Anti-Epidermal Growth Factor Receptor Therapy in <i>RAS/RAF</i> Wild-Type Colorectal Cancer Vary by Regimen and Line of Therapy
Christine M Parseghian, Ryan Sun, Melanie Woods, et al.
The Oncologist
|
February 28, 2026
Phase I Trial of Binimetinib Plus Hydroxychloroquine in Patients with Previously Treated Metastatic Pancreatic Cancer
S Daniel Haldar, Fen Saj, So Jung Hong, et al.
Biomarkers : Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals
|
January 6, 2025
Mutational and co-mutational landscape of early onset colorectal cancer
Jumanah Yousef Alshenaifi, Guglielmo Vetere, Giulia Maddalena, et al.
JCO Precision Oncology
|
July 16, 2025
Phase II Trial of TAS-102 in Colorectal Cancer Patients With Circulating Tumor DNA-Defined Minimal Residual Disease After Adjuvant Therapy: INTERCEPT-TT
Andrew J Pellatt, Alisha Bent, Nicholas Hornstein, et al.
Translational Oncology
|
April 4, 2025
Tumoral and circulating genomic landscape inform survival differences in colorectal carcinomatosis
Michael G White, Reed I Ayabe, Mohammad A Zeineddine, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 8, 2021
ARID1A Mutation May Define an Immunologically Active Subgroup in Patients with Microsatellite Stable Colorectal Cancer
Amir Mehrvarz Sarshekeh, Jumanah Alshenaifi, Jason Roszik, et al.
Page
of 4
Search research articles
Search
Showing results (11-20 of 32) with videos related to
Sort By:
Page
of 4
Pediatrics
|
June 3, 2004
Does an isolated history of loss of consciousness or amnesia predict brain injuries in children after blunt head trauma?
Michael J Palchak, James F Holmes, Cheryl W Vance, et al.
Cancers
|
February 24, 2024
Comprehensive Landscape of BRAF Variant Classes, Clonalities, and Co-Mutations in Metastatic Colorectal Cancer Using ctDNA Profiling
Benny Johnson, Van Morris, Xuemei Wang, et al.
The Oncologist
|
August 10, 2022
Antibiotic Exposure Does Not Impact Immune Checkpoint Blockade Response in MSI-H/dMMR Metastatic Colorectal Cancer: A Single-Center Experience
Victoria Serpas Higbie, Jane Rogers, Hyunsoo Hwang, et al.
JCO Precision Oncology
|
October 12, 2023
Novel Clinical Tool to Estimate Risk of False-Negative KRAS Mutations in Circulating Tumor DNA Testing
Stefania Napolitano, Aparna R Parikh, Jason Henry, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 9, 2022
Resistance Mechanisms to Anti-Epidermal Growth Factor Receptor Therapy in <i>RAS/RAF</i> Wild-Type Colorectal Cancer Vary by Regimen and Line of Therapy
Christine M Parseghian, Ryan Sun, Melanie Woods, et al.
The Oncologist
|
February 28, 2026
Phase I Trial of Binimetinib Plus Hydroxychloroquine in Patients with Previously Treated Metastatic Pancreatic Cancer
S Daniel Haldar, Fen Saj, So Jung Hong, et al.
Biomarkers : Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals
|
January 6, 2025
Mutational and co-mutational landscape of early onset colorectal cancer
Jumanah Yousef Alshenaifi, Guglielmo Vetere, Giulia Maddalena, et al.
JCO Precision Oncology
|
July 16, 2025
Phase II Trial of TAS-102 in Colorectal Cancer Patients With Circulating Tumor DNA-Defined Minimal Residual Disease After Adjuvant Therapy: INTERCEPT-TT
Andrew J Pellatt, Alisha Bent, Nicholas Hornstein, et al.
Translational Oncology
|
April 4, 2025
Tumoral and circulating genomic landscape inform survival differences in colorectal carcinomatosis
Michael G White, Reed I Ayabe, Mohammad A Zeineddine, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 8, 2021
ARID1A Mutation May Define an Immunologically Active Subgroup in Patients with Microsatellite Stable Colorectal Cancer
Amir Mehrvarz Sarshekeh, Jumanah Alshenaifi, Jason Roszik, et al.
Page
of 4